logo
Back Pain Relief From This Therapy Can Last for Years

Back Pain Relief From This Therapy Can Last for Years

WebMDa day ago
back pain treatments that offer lasting relief, or any relief.
That's why a surprising new study, published Wednesday, is drawing public and clinical attention, showing that adults with disabling low-back pain who completed just eight sessions of a novel therapy saw sustained improvements in their pain and activity levels – even after three years.
The treatment, called cognitive functional therapy (CFT), blends physical therapy with a psychology-based approach.
CFT "teaches patients how to manage their own symptoms, what their pain experience means, and how they can move forward without injuring themselves," said Chad E. Cook, PT, PhD, a pain researcher at Duke University in Durham, North Carolina. (Cook was not involved in the study.)
Teaching people to self-manage pain is the cornerstone of the approach, Cook said. It's "why the authors saw improvements at three years – which is very uncommon."
The study included 312 adults in Australia with an average pain level of 4 or more on a 10-point scale – enough to interfere with daily living and work activities.
Of those who completed the CFT (which included seven 30- to 60-minute sessions over 12 weeks, plus an eighth "booster" session at 26 weeks), more than 40% saw improvement in their activity level – and maintained that improvement after three years, compared to 17% in a comparison group who received usual care.
Pain scores dropped by an average of 2 points in the CFT group, compared with less than 1 point in the usual care group, and that was also sustained after three years.
The average age of people in the study was 48, but benefits were seen among a wide range of ages, said study author Mark Hancock, PhD.
Here are three things to know about CFT for low-back pain, a condition that affects more than 1 in 4 U.S. adults.
CFT helped the people that nothing else worked for. Most people in the study did not expect the treatment to work, likely because other treatments they'd tried had failed.
"The poor outcomes of mainstream approaches are one of the reasons the authors created CFT," Cook said. "Before giving up, it is worth speaking with a CFT clinician to determine if the approach is right for you."
People with the most severe low-back pain have the most to gain: They're the ones who tend to reap the greatest benefit from CFT, the research showed.
CFT is low risk and can be done anywhere. There's no clear go-to therapy for low-back pain, and many options – like surgery or opioids – carry high risks. Research on most treatments shows mixed results, and scientists haven't yet figured out how to tailor them to individual patients.
But anyone can do CFT, anywhere. Many of the people in the study did their sessions via virtual appointments, although Hancock recommends doing the first session in person.
It's movement and psychotherapy combined.
A course of CFT is highly personalized, but it might include:
Tailoring therapy based on what's causing your pain – an old back injury or past surgery, for example – and your experiences from treatments that didn't work
Tracking exactly when and where pain shows up – like if it worsens while sitting, climbing stairs, or after certain movements
Challenging unhelpful beliefs about pain, such as "I will never be able to work again" or "my posture is wrong"
Practicing specific movements and psychological strategies with the therapist – like learning to move despite discomfort, training your body not to respond by tensing up (known as muscle guarding), and focusing instead on relaxing the muscles (which can ease pain)
Relearning everyday movements that matter to you – such as standing or sitting without pain, walking the dog, or getting back on the bike – along with strength training and lifestyle habits that support recovery
Developing helpful internal monologues, like "I became mindful to my response to pain" or "I don't fear my pain anymore"
How Do You Get Started with CFT?
Because it's an emerging therapy, you may not readily find a CFT-trained physical therapist. If you can't find one close to you, Hancock suggested searching for a physical therapist who describes themselves as "more of a coach, helping you to understand your back pain and giving you skills and confidence to return to activity."
In the meantime, Hancock, a professor of physiotherapy and back pain researcher at Australia's Macquarie University in Sydney, offers these tips:
Try to keep moving during pain, rather than resting or avoiding activity. Relax and try to move normally.
View your pain as a warning sign, but not as message that damage is happening. If you gradually do more, the pain usually is reduced.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cannabis, Psychedelics Get High Marks for Eating Disorder
Cannabis, Psychedelics Get High Marks for Eating Disorder

Medscape

time39 minutes ago

  • Medscape

Cannabis, Psychedelics Get High Marks for Eating Disorder

TOPLINE: Cannabis and psychedelics were rated as the most effective drugs for symptom relief by survey participants with eating disorders (EDs), including anorexia nervosa, bulimia nervosa, and binge eating disorder (BED). On the other hand, patients perceived prescription antidepressants as mainly providing benefits for overall mental health. METHODOLOGY: Researchers analyzed responses to the international online MED-FED survey between 2022 and 2023. The study included more than 6000 adults (mean age, 24.3 years; 94% women; 82% White) who self-reported an ED (62%) or disordered eating (38%) and were predominantly from Australia (30%), the UK (21%), and the US (18%). The highest percentage of ED type was anorexia nervosa (41%), bulimia nervosa (19%), and BED (11%). Additionally, 65% had comorbid depression. The survey included questions on recent (previous 12 months) use of prescription drugs, caffeine, alcohol, tobacco and nicotine, cannabis, psychedelics, prosocial or party drugs such as 3,4-methylenedioxymethamphetamine and gamma-hydroxybutyric acid, stimulants, and opioids. Participants rated their agreement on a 5-point Likert scale regarding each drug's effects on ED symptoms, overall benefits for mental health, and unpleasant side effects. TAKEAWAY: Cannabis was used by 56% of participants, with its daily use being particularly high among those with avoidant/restrictive food intake disorder (odds ratio, 2.4; P < .001). Psilocybin and cannabis received the highest positive rating for relieving ED symptoms (mean rating, 0.50 for both), followed by lysergic acid diethylamide (mean rating, 0.3). Prescription antidepressants were rated effective for improving overall mental health but not for relieving ED symptoms, with the exceptions of lisdexamfetamine for BED (mean rating, 1.14) and fluoxetine for bulimia nervosa (mean rating, 0.50). Alcohol and amphetamines (mean rating, -0.52 for both) received the poorest ratings for symptom improvement. Unpleasant adverse effects were least likely to be reported with the use of lamotrigine (mean rating, -0.49), illicitly sourced diazepam (mean rating, -0.40), bupropion (mean rating, -0.29), and psilocybin (mean rating, -0.30). IN PRACTICE: 'These findings highlight an important pattern: with traditional medications often falling short in treating eating disorders directly, while many individuals are self-medicating with substances they perceive as helpful,' lead investigator Sarah-Catherine Rodan, the University of Sydney, Sydney, Australia, said in a press release. The results also suggest that 'more research, including large clinical trials, should be undertaken around the beneficial effects of cannabis and psychedelics for people with eating disorders,' she added. SOURCE: The study was published online on July 22 in JAMA Network Open. LIMITATIONS: The study predominantly involved high-income English-speaking countries and participants with internet access, potentially introducing a selection bias. The sample may have also been influenced by novelty-seeking individuals or those with positive experiences with drugs. The reliance on self-diagnosis without formal assessment of EDs or comorbid conditions, along with potential recall bias in self-reporting of drug use and clinical features, limited the generalizability of findings. Some findings involved relatively small numbers of people with specific diagnoses using specific drugs, and the positive public perception of cannabis and psychedelics may have influenced ratings through expectation and placebo effects. DISCLOSURES: The study was funded by the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Several investigators reported having financial ties with various sources, and some reported holding share options, patents, and expert-witness roles with pharmaceutical and cannabis-industry entities. Full details are listed in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

CLL: More Protection, More Problems?
CLL: More Protection, More Problems?

Medscape

time5 hours ago

  • Medscape

CLL: More Protection, More Problems?

TOPLINE: In a 14-year study of 6217 patients with chronic lymphocytic leukemia (CLL), regular immunoglobulin replacement therapy (IgRT) was associated with higher infection rates during treatment periods than during nontreatment periods. Monthly infection-related hospitalizations doubled, while IgRT use quadrupled over the study period. METHODOLOGY: Researchers conducted a retrospective longitudinal analysis of 6217 patients diagnosed with CLL between 2008 and 2022 in Victoria, Australia, using linked hospital and death data. Analysis included Kaplan-Meier survival analyses to estimate survival, infection incidence, and IgRT use, while Cox survival analyses explored associations between infections and IgRT in regular prophylactic users. Investigators tracked 753 patients (12.1%) who received IgRT, with 524 (8.4%) receiving regular treatment, defined as at least three IgRT sessions within a 5-month period, with no gaps longer than 3 months. TAKEAWAY: Patients experiencing serious infections showed significantly higher mortality rates (0.090; 95% CI, 0.074-0.110) than those without infections (0.008; 95% CI, 0.007-0.009). Regular IgRT users demonstrated higher infection incidence during treatment periods (0.056; 95% CI, 0.052-0.060) vs nontreatment periods (0.038; 95% CI, 0.035-0.042). Serious infections were strongly associated with IgRT initiation (hazard ratio [HR], 31.91; 95% CI, 24.94-40.82) and cessation (HR, 3.81; 95% CI, 2.71-5.35). The median survival time from CLL diagnosis was 10 years, with infection-related hospitalizations doubling, while IgRT use quadrupled over the 14-year follow-up period. IN PRACTICE: 'Given the increasing use and costs of IgRT, these results highlight the need to evaluate the causal association between IgRT and infections and determine which patient subgroup, and at what point during their disease course, may benefit the most from IgRT treatment. Further research, particularly randomized controlled trials, is needed to fully understand the effectiveness and cost-effectiveness of IgRT in this patient population,' wrote the authors of the study. SOURCE: The study was led by Sara Carrillo de Albornoz, School of Public Health and Preventive Medicine, Monash University in Melbourne, Australia. It was published online in Blood Advances. LIMITATIONS: According to the authors, the retrospective design and potential selection bias were significant limitations. The study lacked key clinical prognostic factors, disease severity data, and cancer treatment-related information. Additionally, researchers could not stratify patients or adjust for infection risk, particularly underlying hypogammaglobulinemia. The analysis was limited to serious infections, while outpatient infections and oral antibiotic treatments outside of hospital were not captured. DISCLOSURES: The study was funded by the Medical Research Future Fund Value-Ig Study. Erica Wood and Zoe McQuilten disclosed receiving grant funding from CSL Behring unrelated to this study and research funding to their institution from Abbvie, Amgen, AstraZeneca, Beigene, Celgene, Janssen, New Zealand Blood Service, Novartis, Sanofi, and Takeda. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Scientists say the Great Barrier Reef is 'worth fighting for' after shocking report
Scientists say the Great Barrier Reef is 'worth fighting for' after shocking report

Yahoo

time6 hours ago

  • Yahoo

Scientists say the Great Barrier Reef is 'worth fighting for' after shocking report

A new report has found that parts of the Great Barrier Reef have suffered the largest annual decline in coral cover since records began almost 40 years ago. According to the Australian Institute of Marine Science (AIMS), the sharp declines in coral cover and increased instances of coral bleaching are directly linked to heat stress caused by climate change–but scientists are warning Aussies that despair isn't the answer. The AIMS research team leader for reef monitoring, Dr Mike Emslie, told Yahoo News Australia that while the latest report does highlight the seriousness of increased coral bleaching, the reef is still 'worth fighting for.' 'It is by no means dead, but it is certainly under stress from continuous cumulative impacts… if we do give it a chance by taking meaningful action on greenhouse gas emissions and getting the warming trend under control, it will continue to flourish into the future.' Video transcript A new report has found that parts of the Great Barrier Reef have suffered the largest annual decline in coral cover since records began almost 40 years ago, according to the Australian Institute of Marine Science. The sharp decline in coral cover and increased instances of coral bleaching are directly linked to heat stress caused by climate change, but scientists are warning Aussies that despair isn't the answer. The AIMS research team leader for Monitoring, Dr. Mike Emsley told Yahoo News Australia that while the latest report does highlight the seriousness of increased coral bleaching, the reef is still worth fighting for. It is by no means dead, but it is certainly under stress from continuous cumulative impacts. If we do give it a chance by taking meaningful action on greenhouse gas emissions and getting the warming trend under control, it will continue to flourish into the future.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store